Research & Development
Indiana University, MindX Sciences researchers developing blood test for anxiety
A blood test for anxiety may determine an individual’s risk of developing anxiety, and which therapies might treat it most effectively, the researchers said.
March 8, 2023
Study supports genetic testing for people with cerebral palsy
A meta-analysis of recent cerebral palsy research suggests that genetic testing could be offered as the standard procedure for people with the disorder.
March 7, 2023
Quanterix Q4 revenues drop 15% but match analysts’ expectations
For full-year 2022, total revenue was $105.5 million, a decline of 5% compared with 2021 revenue that included $5.2 million in National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) grant money.
March 6, 2023
Invitae announces data on epilepsy genetic testing outcomes
Among patients whose treatment was changed based on genetic testing, 75% reported positive health outcomes, including 65% who saw a reduction in frequency -- even elimination -- of seizures.
November 1, 2022
Variantyx obtains $20M in funding
Whole genome sequencing tracks changes in genes that can cause disease. Variantyx is developing the testing method for the diagnosis of rare inherited and neurological disorders, it said.
March 15, 2021
Researchers outline neurological signs of COVID-19
The neurological complications of COVID-19 are becoming more obvious as the pandemic wears on, and they consist of a startling range of conditions, according to a team led by Ross Paterson, PhD, of University College London.
July 8, 2020
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
Real-world study: Genetic testing appears underused in autism
Neurological medicine researchers evaluated how frequently chromosomal microarray (CMA) and fragile X syndrome testing were conducted in people with autism spectrum disorder through the Rhode Island Consortium for Autism Research and Treatment (RI-CART). Results were reported by Dr. Eric Morrow, PhD, head of the Developmental Disorders Genetics Research Program at Brown University, and colleagues in a research letter.
May 13, 2020
Pathology study challenges conventional wisdom on brain injury
The prospective Traumatic Head Injury Neuroimaging Classification (THINC) study was funded by the U.S. Department of Defense and the National Institute of Neurological Disorders and Stroke (NINDS).
October 14, 2019
FYR gets NIH small business grant for epilepsy diagnostics
The grant was awarded by the NIH's National Institute of Neurological Disorders and Stroke, through the government's Small Business Innovation Research program. In the first phase of the funding, FYR Diagnostics will develop biomarkers for use in diagnostic kits.
October 9, 2019
Invitae offers 4 more no-charge genetic tests
These four conditions were chosen because testing is underutilized, so there is room to improve diagnosis and treatment, the company explained in a statement. Patients who meet eligibility criteria can access Invitae's company- and organization-sponsored testing programs by enrolling through their doctors. The sponsors get deidentified information and contact information from participating clinicians.
July 23, 2019
Intensive blood sugar control has low value in acute stroke
The trial -- dubbed the Stroke Hyperglycemia Insulin Network Effort (SHINE) -- compared intensive and standard blood glucose control using insulin in 1,151 acute stroke patients and showed good outcomes for 20% in both cohorts, Dr. Karen Johnston, chair of neurology at the University of Virginia, and colleagues reported (JAMA, July 23/30, 2019, Vol. 322:4, pp. 326-335).
July 23, 2019
Cerebrospinal fluid test helps pinpoint dementia disorders
The meta-analysis of studies involving about 10,000 people with neurological disorders showed that neurofilament light protein as measured with a commercially available immunoassay was elevated for people with neurological and psychiatric conditions. Results were broadly similar; however, frontotemporal dementia and HIV-related cognitive decline were differentiated from other dementias, and Parkinson's disease was differentiated from atypical parkinsonian conditions.
June 17, 2019
Page 1 of 1